KEI Comments on NIH Exclusive License to Australian firm SubRed

On Monday April 26, 2021, Knowledge Ecology International submitted comments regarding the “Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype” (86 FR 18545) by the… Continue Reading

KEI Comments Regarding NIH Exclusive License to Memorial Sloan Kettering Cancer Center

(Update: The NIH provided a response to our comments on April 15, 2021.) Knowledge Ecology International (KEI) submitted comments on April 14, 2021 to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of Exclusive Patent… Continue Reading